Tepoxalin

Drug Profile

Tepoxalin

Alternative Names: ORF 20485; RWJ 20485

Latest Information Update: 01 Dec 1995

Price : $50

At a glance

  • Originator Ortho-McNeil
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics
  • Mechanism of Action 5-lipoxygenase inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Osteoarthritis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 01 Dec 1995 A preclinical study has been added to the Transplant Rejection pharmacodynamics section
  • 09 Mar 1995 A preclinical study has been added to the Rheumatic Disease pharmacodynamics section
  • 20 Feb 1995 Discontinued-II for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top